GRAIL, Inc.
GRALGRAIL, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (10 weeks in). Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
GRAIL, Inc. trades at $72.7, building a base and 10 weeks into that stage. That is −2.1% against its own 200-day average. It sits at 52% of a 52-week range of $32 to $110. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 12 straight weeks.
Today the stock is building a base — week 10 of stage 1. At $72.7 it trades −2.1% versus its 200-day average and sits at 52% of its 52-week range ($32–$110).
Against the market, two honest reads. Cumulative: over the last 2.1 years the stock moved +397% while the S&P 500 moved +42% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 12 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price GRAIL, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values GRAIL, Inc. at 20.0× its FY25 revenue of $0.1 B.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
GRAIL, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +15.4% | — | — | — |
| Stock price | +121.7% | — | — | — |
4-Factor Sector Score
38.8/100 — rank 24 of 30 in Diagnostics & Research · 61% evidence confidence
GRAIL, Inc. scores 38.8 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 24. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.2 + 4.7 + 10 + 2.9 = 38.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
GRAIL, Inc. reported $0.0 B of revenue in the Mar 26 quarter, +33.3% year on year. Over 2 years it has compounded at 58.1% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.2 B.
FY25 revenue came in at $0.1 B (+15.4% on the year), capping 2 years at 58.1% compound. The latest quarter (Mar 26) printed $0.0 B, +33.3% year on year.
Pace check: the last four quarters averaged +25.0% growth against the decade's 58.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +23.1% over the last 4 quarters against +26.5%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
GRAIL, Inc.'s operating margin is −350.0% in the Mar 26 quarter, +150.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −9,066.7% to −373.3%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is −350.0%, +150.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −9,066.7%–−373.3%.
Why the margin moved: operating margin went +150.0 pp year on year while gross margin went +16.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
GRAIL, Inc. posted a net loss of $0.1 B in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY25 year was a loss of $0.4 B. That loss is 225.0% of the quarter's revenue.
Mar 26 profit was $−0.1 B, null year on year. On the full year, FY25 printed $−0.4 B (null).
🚨 Read this profit with care: at $−0.1 B it is larger than the whole quarter's revenue of $0.0 B — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −350.0% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
GRAIL, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.3 B of operating cash against $−0.4 B of profit. After $0.0 B of capital spending, $−0.3 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.3 B against reported profit of $−0.4 B, leaving free cash of $−0.3 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
GRAIL, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
GRAIL, Inc. earns a ROE of −16% in FY25. That is up from a trough of −81% in FY24. Return on invested capital clears the cost of that capital by −34.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −273.3% net margin on 0.05× asset turns.
FY25 ROE is −16%, recovered from a FY24 trough of −81% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −273.3% net margin × 0.05× asset turns × 1.13× balance-sheet leverage ≈ −15.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −12.8% − 21.6% = a −34.4 pp spread. The 21.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
GRAIL, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
GRAIL, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
GRAIL, Inc. carries total debt of $0.1 B against shareholder equity of $2.5 B as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.00 in FY18 to 0.02 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.1 B against shareholder equity of $2.5 B — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.00 (FY18) to 0.02 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
23.1% of GRAIL, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 12.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 23.1% of the float is sold short, and at typical trading volumes it would take about 12.7 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
GRAIL, Inc.: the Z-score reads −0.91. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of −0.91 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads −0.91.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Medpace Holdings, Inc.MEDP | 60.6/100Thin evidence · provisional58% evidence | TURNING | 21.1/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 21.3/25 ROCE 30.2% · OPM 20% 76% evidence | 10.5/20 P/E 31× · PEG — 15% evidence | 7.7/20 RS sector -13.3% · RS bench 0.3% · 1Y 32.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 21.3 + 10.5 + 7.7 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Agilent Technologies, Inc.A | 56.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 95% evidence | 16.1/25 ROCE 3.8% · OPM 21.7% 76% evidence | 14.4/20 P/E 23.2× · PEG 1.01 65% evidence | 3.8/20 RS sector -17.5% · RS bench -4.3% · 1Y 21.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.1 + 14.4 + 3.8 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Illumina, Inc.ILMN | 56.5/100Thin evidence · provisional58% evidence | LEADER | 18.1/35 Revenue — · PAT — · OPM change 3.4 pp 45% evidence | 14.3/25 ROCE 5.1% · OPM 19.2% 76% evidence | 10.3/20 P/E 32.9× · PEG — 15% evidence | 13.8/20 RS sector 18.4% · RS bench 36.7% · 1Y 114.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 10.3 + 13.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Adaptive Biotechnologies CorporationADPT | 55.5/100Thin evidence · provisional55% evidence | BREAKING OUT | 21.6/35 Revenue — · PAT — · OPM change 29.3 pp 45% evidence | 5.7/25 ROCE -3.3% · OPM -27.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.2/20 RS sector 19.2% · RS bench 37.1% · 1Y 101.2%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 5.7 + 10 + 18.2 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5NeoGenomics, Inc.NEO | 54.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.0/35 Revenue — · PAT — · OPM change 6.8 pp 45% evidence | 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence | 9.0/20 P/E 134× · PEG — 15% evidence | 18.7/20 RS sector 22.1% · RS bench 39.9% · 1Y 180.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6 + 9 + 18.7 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6IDEXX Laboratories, Inc.IDXX | 54.1/100Mixed-positive evidence81% evidence | TURNING | 22.8/35 Revenue 13.1% · PAT 22.4% · OPM change 0.1 pp 83% evidence | 20.1/25 ROCE 17.4% · OPM 31.8% 76% evidence | 10.1/20 P/E 41.4× · PEG 1.62 65% evidence | 1.1/20 RS sector -27.4% · RS bench -15.5% · 1Y -10.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 20.1 + 10.1 + 1.1 = 54.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -27.4% and the one-year return is -10.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Mettler-Toledo International Inc.MTD | 53.9/100Thin evidence · provisional58% evidence | TURNING | 17.4/35 Revenue — · PAT — · OPM change -0.8 pp 45% evidence | 18.4/25 ROCE 12.9% · OPM 23.9% 76% evidence | 10.6/20 P/E 28.8× · PEG — 15% evidence | 7.5/20 RS sector -15.6% · RS bench -2% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 18.4 + 10.6 + 7.5 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Quest Diagnostics IncorporatedDGX | 52.5/100Thin evidence · provisional58% evidence | TURNING | 17.0/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 14.7/25 ROCE 3.2% · OPM 13.8% 76% evidence | 11.2/20 P/E 22.5× · PEG — 15% evidence | 9.6/20 RS sector -6.6% · RS bench 8.8% · 1Y 32.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 14.7 + 11.2 + 9.6 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Natera, Inc.NTRA | 51.3/100Mixed-positive evidence61% evidence | BREAKING OUT | 21.3/35 Revenue 36.6% · PAT — · OPM change 2.4 pp 62% evidence | 5.4/25 ROCE -5.5% · OPM -13.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 1.4% · RS bench 17% · 1Y 81.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 5.4 + 10 + 14.6 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Charles River Laboratories International, Inc.CRL | 50.7/100Mixed-positive evidence64% evidence | BREAKING OUT | 18.0/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 62% evidence | 11.7/25 ROCE 1.8% · OPM 12% 76% evidence | 8.8/20 P/E 427.2× · PEG — 15% evidence | 12.2/20 RS sector -0.8% · RS bench 14.6% · 1Y 57.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.7 + 8.8 + 12.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Labcorp Holdings Inc.LH | 50.7/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 13.3/25 ROCE 2.8% · OPM 10.8% 76% evidence | 11.1/20 P/E 23.2× · PEG — 15% evidence | 8.8/20 RS sector -11.2% · RS bench 3.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 13.3 + 11.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Twist Bioscience CorporationTWST | 50.6/100Mixed-positive evidence61% evidence | BREAKING OUT | 16.7/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 62% evidence | 4.7/25 ROCE -8.5% · OPM -41.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.2/20 RS sector 59.8% · RS bench 84.2% · 1Y 287.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 4.7 + 10 + 19.2 = 50.6 · Decision use: Price leads the evidence: RS versus the benchmark is 84.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13IQVIA Holdings Inc.IQV | 50.0/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.0/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence | 13.7/25 ROCE 2.4% · OPM 12.4% 76% evidence | 10.8/20 P/E 24× · PEG — 15% evidence | 9.5/20 RS sector -10.1% · RS bench 4% · 1Y 26.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 13.7 + 10.8 + 9.5 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Veracyte, Inc.VCYT | 49.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 21.2/35 Revenue — · PAT — · OPM change 13.8 pp 45% evidence | 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence | 9.5/20 P/E 41.7× · PEG — 15% evidence | 7.5/20 RS sector -9.6% · RS bench 4.2% · 1Y 69.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11 + 9.5 + 7.5 = 49.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15CareDx, Inc.CDNA | 48.7/100Thin evidence · provisional52% evidence | BREAKING OUT | 15.5/35 Revenue — · PAT — · OPM change 16.8 pp 45% evidence | 4.7/25 ROCE -28.5% · OPM 1% 76% evidence | 11.5/20 P/E 13.8× · PEG — 15% evidence | 17.0/20 RS sector 81.9% · RS bench 108.8% · 1Y 293.4%12 of 12 weeks ahead 70% evidence |
| Exact sum: 15.5 + 4.7 + 11.5 + 17 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Guardant Health, Inc.GH | 48.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 14.4 pp 45% evidence | 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.6/20 RS sector 25% · RS bench 43.3% · 1Y 194.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 4.3 + 10 + 17.6 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Sotera Health CompanySHC | 48.1/100Mixed-negative evidence64% evidence | BREAKING OUT | 19.3/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 62% evidence | 14.3/25 ROCE 2.6% · OPM 27.1% 76% evidence | 9.9/20 P/E 35× · PEG — 15% evidence | 4.6/20 RS sector -14.7% · RS bench -1% · 1Y 29.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 14.3 + 9.9 + 4.6 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Thermo Fisher Scientific Inc.TMO | 46.3/100Thin evidence · provisional58% evidence | TURNING | 17.5/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 14.2/25 ROCE 2.2% · OPM 16.9% 76% evidence | 10.7/20 P/E 27.6× · PEG — 15% evidence | 3.9/20 RS sector -16.8% · RS bench -3.6% · 1Y 22.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 14.2 + 10.7 + 3.9 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Qiagen N.V.QGEN | 45.7/100Mixed-negative evidence71% evidence | TURNING | 15.7/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 83% evidence | 12.9/25 ROCE 1.6% · OPM 17.1% 76% evidence | 11.4/20 P/E 20.9× · PEG — 15% evidence | 5.7/20 RS sector -27.4% · RS bench -15.6% · 1Y -16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.9 + 11.4 + 5.7 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Danaher CorporationDHR | 44.5/100Thin evidence · provisional58% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 13.8/25 ROCE 1.4% · OPM 22.6% 76% evidence | 10.1/20 P/E 34.8× · PEG — 15% evidence | 2.1/20 RS sector -26% · RS bench -14.1% · 1Y -2.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 13.8 + 10.1 + 2.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Castle Biosciences, Inc.CSTL | 43.2/100Thin evidence · provisional52% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence | 6.8/25 ROCE -0.6% · OPM -22% 76% evidence | 9.3/20 P/E 43× · PEG — 15% evidence | 8.2/20 RS sector -12.6% · RS bench 0.4% · 1Y 61.1%2 of 12 weeks ahead 70% evidence |
| Exact sum: 18.9 + 6.8 + 9.3 + 8.2 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Revvity, Inc.RVTY | 42.8/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.2/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence | 9.4/20 P/E 42.6× · PEG — 15% evidence | 6.7/20 RS sector -11.4% · RS bench 2.7% · 1Y 28.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 11.5 + 9.4 + 6.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23OPKO Health, Inc.OPK | 42.8/100Thin evidence · provisional52% evidence | TURNING | 21.2/35 Revenue — · PAT — · OPM change 3.7 pp 45% evidence | 7.1/25 ROCE -0.4% · OPM -41.1% 76% evidence | 10.2/20 P/E 33.2× · PEG — 15% evidence | 4.3/20 RS sector -23.4% · RS bench -10.7% · 1Y 4.8%9 of 12 weeks ahead 70% evidence |
| Exact sum: 21.2 + 7.1 + 10.2 + 4.3 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24GRAIL, Inc.this pageGRAL | 38.8/100Mixed-negative evidence61% evidence | BREAKING OUT | 21.2/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 62% evidence | 4.7/25 ROCE -4.9% · OPM -332.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -16.4% · RS bench -4.6% · 1Y 121.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 4.7 + 10 + 2.9 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25ICON Public Limited CompanyICLR | 38.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 13.8/35 Revenue — · PAT — · OPM change -2.8 pp 45% evidence | 10.5/25 ROCE 1% · OPM 8.5% 76% evidence | 8.9/20 P/E 310.2× · PEG — 15% evidence | 5.5/20 RS sector -20.7% · RS bench -8.3% · 1Y -1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 10.5 + 8.9 + 5.5 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Waters CorporationWAT | 38.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 12.0/35 Revenue — · PAT — · OPM change -28.1 pp 45% evidence | 9.6/25 ROCE -0.4% · OPM -3.7% 76% evidence | 9.8/20 P/E 38.7× · PEG — 15% evidence | 6.9/20 RS sector -11.4% · RS bench 2.6% · 1Y 40.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 9.6 + 9.8 + 6.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27RadNet, Inc.RDNT | 37.9/100Mixed-negative evidence64% evidence | TURNING | 17.9/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 62% evidence | 8.3/25 ROCE -0.8% · OPM -4.2% 76% evidence | 8.6/20 P/E 1746× · PEG — 15% evidence | 3.1/20 RS sector -21.2% · RS bench -8.5% · 1Y 29.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 8.3 + 8.6 + 3.1 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Personalis, Inc.PSNL | 37.0/100Thin evidence · provisional55% evidence | BREAKING OUT | 7.3/35 Revenue -27.6% · PAT — · OPM change -122 pp 62% evidence | 3.7/25 ROCE -12.1% · OPM -207.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.0/20 RS sector 24.8% · RS bench 42.5% · 1Y 199.8%11 of 12 weeks ahead 70% evidence |
| Exact sum: 7.3 + 3.7 + 10 + 16 = 37 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29GeneDx Holdings Corp.WGS | 30.9/100Adverse evidence64% evidence | TURNING | 12.6/35 Revenue 33.8% · PAT — · OPM change -51 pp 62% evidence | 4.1/25 ROCE -14.4% · OPM -56.2% 76% evidence | 8.5/20 P/E 2693.5× · PEG — 15% evidence | 5.7/20 RS sector -43.7% · RS bench -34.9% · 1Y -32.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 4.1 + 8.5 + 5.7 = 30.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30BillionToOne, Inc.BLLN | 58.3/100Thin evidence · provisional44% evidence | BREAKING OUT | 26.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 62% evidence | 13.1/25 ROCE 3.9% · OPM 16.5% 76% evidence | 9.2/20 P/E 60.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 26 + 13.1 + 9.2 + 10 = 58.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is GRAIL, Inc.'s stock price today?
GRAIL, Inc. trades at $72.7, +121.7% over the past year. The company is valued at $3.0 B. The stock sits at 52% of its 52-week range of $32–$110, −2.1% versus its 200-day average. On the tape, the price is building a base, 10 weeks in. — as of 5 August 2026.
What were GRAIL, Inc.'s latest quarterly results?
GRAIL, Inc. reported revenue of $0.0 B and a net loss of $0.1 B for the Mar 26 quarter. Earnings per share were $−2.29. The operating margin was −350.0%, 150.0 pp higher than a year earlier. — as of 5 August 2026.
What is GRAIL, Inc.'s revenue?
GRAIL, Inc. reported revenue of $0.0 B in the Mar 26 quarter, +33.3% year on year. For the full FY25 fiscal year, revenue was $0.1 B (+15.4%). Over the last 2 years revenue compounded at 58.1% a year. — as of 5 August 2026.
What is GRAIL, Inc.'s profit?
GRAIL, Inc. earned $−0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.4 B. The operating margin ran −350.0% in the latest quarter. — as of 5 August 2026.
What is GRAIL, Inc.'s market cap?
GRAIL, Inc.'s market capitalisation is $3.0 B at a stock price of $72.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does GRAIL, Inc. pay a dividend?
No — GRAIL, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is GRAIL, Inc. performing?
GRAIL, Inc. is building a base, 10 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 12 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is GRAIL, Inc. in an uptrend?
No — the price is building a base (week 10 of stage 1), trading −2.1% versus its 200-day average and at 52% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is GRAIL, Inc. beating the market?
On recent form, yes — GRAIL, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 12 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.1 years the stock moved +397% against the S&P 500's +42% — ahead of the index over the full window. — as of 5 August 2026.
Will GRAIL, Inc.'s stock price go up?
This page publishes no price forecast for GRAIL, Inc. What it measures instead: the stock price is $72.7, the price is building a base 10 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against GRAIL, Inc.?
Yes — short interest is 23.1% of GRAIL, Inc.'s tradable float, about 12.7 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does GRAIL, Inc. have too much debt?
No — GRAIL, Inc.'s debt-to-equity is 0.02. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is GRAIL, Inc.'s capex?
GRAIL, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is GRAIL, Inc.'s cash flow?
GRAIL, Inc. generated $−0.3 B of operating cash flow in FY25 and $−0.3 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.4 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is GRAIL, Inc.?
On the balance sheet, the Z-score reads −0.91 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.
Where is GRAIL, Inc. in its business cycle?
GRAIL, Inc.'s FY25 operating margin was −373.3%, against a 4-year band of −9,066.7%–−373.3%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −350.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the GRAIL, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is GRAIL, Inc. a stock worth studying right now?
This is not investment advice. The machine read: GRAIL, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.